Takeda Pharmaceuticals Shares Rise on Positive Psoriasis Treatment Results
I'm PortAI, I can summarize articles.
Takeda Pharmaceuticals' shares rose 4.3% in early Tokyo trade after announcing positive Phase 3 trial results for its new psoriasis treatment, zasocitinib. The drug showed significant efficacy in treating plaque psoriasis, leading to expectations of a new drug application with the FDA by 2026. Citi Research forecasts annual sales of 150 billion yen for the drug, with a launch expected by March 2027.
Source: marketscreener The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments